20092019

Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Francesco Galimi is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 15 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours

Martin, V., Chiriaco, C., Modica, C., Acquadro, A., Cortese, M., Galimi, F., Perera, T., Gammaitoni, L., Aglietta, M., Comoglio, P. M., Vigna, E. & Sangiolo, D., Mar 2019, In : British Journal of Cancer. 120, 5, p. 527-536 10 p.

Research output: Contribution to journalArticle

  • Selective analysis of cancer-cell intrinsic transcriptional traits defines novel clinically relevant subtypes of colorectal cancer

    Isella, C., Brundu, F., Bellomo, S. E., Galimi, F., Zanella, E., Porporato, R., Petti, C., Fiori, A., Orzan, F., Senetta, R., Boccaccio, C., Ficarra, E., Marchionni, L., Trusolino, L., Medico, E. & Bertotti, A., May 31 2017, In : Nature Communications. 8, 15107.

    Research output: Contribution to journalArticle

  • HER2 activating mutations are targets for colorectal cancer treatment

    Kavuri, S. M., Jain, N., Galimi, F., Cottino, F., Leto, S. M., Migliardi, G., Searleman, A. C., Shen, W., Monsey, J., Trusolino, L., Jacobs, S. A., Bertotti, A. & Bose, R., Aug 1 2015, In : Cancer Discovery. 5, 8, p. 832-841 10 p.

    Research output: Contribution to journalArticle

  • IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies

    Zanella, E. R., Galimi, F., Sassi, F., Migliardi, G., Cottino, F., Leto, S. M., Lupo, B., Erriquez, J., Isella, C., Comoglio, P. M., Medico, E., Tejpar, S., Budinská, E., Trusolino, L. & Bertotti, A., Jan 28 2015, In : Science Translational Medicine. 7, 272, 272ra12.

    Research output: Contribution to journalArticle

  • Intrinsic resistance to MEK inhibition in kras mutant lung and colon cancer through transcriptional induction of ERBB3

    Sun, C., Hobor, S., Bertotti, A., Zecchin, D., Huang, S., Galimi, F., Cottino, F., Prahallad, A., Grernrum, W., Tzani, A., Schlicker, A., Wessels, L. F. A., Smit, E. F., Thunnissen, E., Halonen, P., Lieftink, C., Beijersbergen, R. L., DiNicolantonio, F., Bardelli, A., Trusolino, L. & 1 others, Bernards, R., Oct 4 2014, In : Cell Reports. 7, 1, p. 86-93 8 p.

    Research output: Contribution to journalArticle